Treating cancer by targeting a weakness

被引：36

作者：

Brody, LC ^{[1
]}

机构：

[1] NHGRI, Genome Technol Branch, NIH, Bethesda, MD 20892 USA

来源：

NEW ENGLAND JOURNAL OF MEDICINE | 2005年 / 353卷 / 09期

关键词：

D O I：

10.1056/NEJMcibr052331

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

[No abstract available]

引用

页码：949 / 950

页数：2

共 3 条

[1] Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase [J].

Bryant, HE ;

Schultz, N ;

Thomas, HD ;

Parker, KM ;

Flower, D ;

Lopez, E ;

Kyle, S ;

Meuth, M ;

Curtin, NJ ;

Helleday, T .

NATURE, 2005, 434 (7035) :913-917

[2] Loss of poly(ADP-ribose) polymerase-1 causes increased tumour latency in p53-deficient mice [J].

Conde, C ;

Mark, M ;

Oliver, FJ ;

Huber, A ;

de Murcia, G ;

Ménissier-de Murcia, J .

EMBO JOURNAL, 2001, 20 (13) :3535-3543

[3] Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy [J].

Farmer, H ;

McCabe, N ;

Lord, CJ ;

Tutt, ANJ ;

Johnson, DA ;

Richardson, TB ;

Santarosa, M ;

Dillon, KJ ;

Hickson, I ;

Knights, C ;

Martin, NMB ;

Jackson, SP ;

Smith, GCM ;

Ashworth, A .

NATURE, 2005, 434 (7035) :917-921

← 1 →